Dr. Reddy’s relaunches OTC generic famotidine tablets
Dr. Reddy’s is bringing its equivalent of Pepcid AC back to the U.S. market. The company is relaunching its famotidine tablets in 10- and 20-mg tablets, store-brand equivalents of original strength and maximum strength Pepcid AC.
The product is an acid reducer that prevents and relieves heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods or beverages.
"We are pleased to continue to expand our OTC Antacid portfolio for our customers and consumers,” says Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories. “This launch will help us fulfil an important therapy gap created in Antacids market due to Ranitidine withdrawal.”
Pepcid AC had brand and generic sales of roughly $211 million for the year ended August 2020, according to IRI